RATIONALE-306 subgroup analysis in advanced/metastatic ESCC with TAP score ≥ 5%

In the RATIONALE-306 trial, first-line treatment with tislelizumab (TIS) plus chemotherapy (CT) demonstrated a significant OS benefit over placebo + CT in patients with advanced ESCC, both in the overall population and in those with PD-L1 TAP score ≥10%, at both the primary analysis and 3-year follow-up. The current analysis focuses on patients with PD-L1 TAP score ≥5%. In this subgroup, TIS+CT achieved a median OS of 19.1 months, representing a new benchmark for efficacy in advanced/metastatic ESCC. These benefits were consistent with prior analyses, with durable outcomes and no new safety concerns.